首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
【24h】

Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry

机译:通过质谱法澄清全身和局部免疫球蛋白轻链淀粉样蛋白病变中的免疫球蛋白基因使用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Thegoal of this studywasto investigate the frequency of use of light-chain variable region (IGVL) genes among patients with systemic (ALS) and localized (ALL) amyloidosis and to assess for associations between IGVL gene usage and organ tropism. Weevaluated clinic charts from 821 AL patients seen at the Mayo Clinic who had bone marrow, fat pad, and solid organ tissue samples typed by liquid chromatography tandem mass spectrometry (LC-MS). We identified 701 patients with ALS and 120 with ALL. Overall, we were able to identify an IGVL gene in 87 (72%) patients with ALL and 573 (82%) patients with ALS. When compared with ALL, LV6-57 was more common, whereas KV3-20 and heavy-chain codeposition were less common in ALS. In this large series of ALS, characteristics particular to specific genotypes became apparent. LV6-57 patients were more likely to have renal involvement and to harbor a translocation 11;14. LV3-01 patients were less likely to haveadvancedcardiac diseaseandrenal involvement. LV2-14 patientsweremore likely to have peripheral nerve involvement, an intact circulating immunoglobulin, and lower circulating dFLC. LV1-44 patients were more likely to have cardiac involvement. KV1-33 patients had more liver involvement and higher circulating dFLC. Finally, KV1-05 was associated with inferior overall survival but not independently of cardiac stage. IGVL gene usage appears to provide clues about disease pathophysiology and tissue tropism. LC-MS is a high-throughput and low-resource technique that can be used to identify IGVL gene from clinical tissue specimens.
机译:本研究的技术探讨了全身(ALS)患者和局部(全部)淀粉样症患者的轻链可变区(IGVL)基因的使用频率,并评估IGVL基因使用与器官矫正性之间的关联。从821岁的梅奥诊所看到的患者患者临床图表,患有骨髓,脂肪垫和由液相色谱串联质谱(LC-MS)键入的固体器官组织样品。我们确定了701名患有ALS和120的患者。总体而言,我们能够在87名(72%)患者中识别IGVL基因所有和573名(82%)患者的ALS患者。与全部相比,LV6-57更常见,而KV3-20和重链负数在ALS中不太常见。在这大系列ALS中,特征特征对特定基因型变得明显。 LV6-57患者更有可能具有肾脏受累和港口易位11; 14。 Lv3-01患者不太可能避免VACTADCARDIACIAC患者的参与。 LV2-14患者可能具有外周神经受累,完整的循环免疫球蛋白,以及下循环DFLC。 LV1-44患者更有可能具有心脏受累。 KV1-33患者具有更多肝脏受累和更高的循环DFLC。最后,KV1-05与劣质的整体存活有关,但不能独立于心脏阶段。 IGVL基因使用似乎提供有关疾病病理生理和组织抗性的线索。 LC-MS是一种高通量和低资源技术,可用于识别来自临床组织标本的IGVL基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号